As of February 1, 2008, we have more than 35 partnerships with pharmaceutical and biotechnology companies to jointly develop and commercialize products or to enable other companies to use our UltiMAb technology in their development and commercialization of new therapeutic products. While we have collaborations involving co-promotion and in-licensing agreements, in general, our partnerships fall into two major categories: (1) collaborative partnerships in which we collaborate with partners to jointly generate, develop and commercialize human antibody products; and (2) out-licensing partnerships in which we license our human antibody generation technology to our partners in exchange for license fees, milestone payments, and royalties.
We have continued to increase our access to novel therapeutic targets by establishing collaborations with other companies and institutions that have identified potential therapeutic targets or have created platforms for the identification of such targets. We actively seek opportunities to in-license and/or acquire such targets and intend to develop novel therapeutic products by producing fully human antibodies that interact with such targets.
could be a potential partner?????????????????????????
D
Market Data 
Markets 
AI
